Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 31;14:1125948. doi: 10.3389/fimmu.2023.1125948

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Al Aameri, Alanisi, Oluwatosin, Al Sallami, Sheth, Alberts, Patel, Rybak and Ramkumar

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

SB225002 suppresses cisplatin modulation of pro-inflammatory genes. (A) Cisplatin induced inflammatory genes were assessed 72 h following cisplatin treatment. The expression of cochlear CXCR2, CXCR1, CXCL1, NOX3, iNOS, TNFα, IL-6, IL-10, STAT1 and COX2 genes were significantly increased by cisplatin. In rats treated with SB225002 (1.4 nmoles/ear) the response to cisplatin was attenuated (P>0.0008, F(3,40)=6.8 and D.F. = 43) (B) The ratios of STAT3:STAT1, derived from (A), were suppressed by cisplatin, normalized in the SB225002 + cisplatin group but significantly enhanced by SB225002 alone. Asterisk, (*) indicates significant difference from vehicle group while (**) indicate statistically significant difference from cisplatin-treated group. Statistical significance from vehicle-treated rats which was determined by analysis of variance (one-way ANOVA).